Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Cash & Equivalents (2023 - 2025)

Rallybio's Cash & Equivalents history spans 3 years, with the latest figure at $32.1 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 26.86% year-over-year to $32.1 million; the TTM value through Sep 2025 reached $32.1 million, up 26.86%, while the annual FY2024 figure was $13.9 million, 43.24% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $32.1 million at Rallybio, up from $9.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $39.5 million in Q1 2023 and bottomed at $9.4 million in Q2 2025.
  • The 3-year median for Cash & Equivalents is $19.3 million (2024), against an average of $22.5 million.
  • The largest YoY upside for Cash & Equivalents was 32.16% in 2024 against a maximum downside of 51.16% in 2024.
  • A 3-year view of Cash & Equivalents shows it stood at $24.5 million in 2023, then crashed by 43.24% to $13.9 million in 2024, then surged by 131.04% to $32.1 million in 2025.
  • Per Business Quant, the three most recent readings for RLYB's Cash & Equivalents are $32.1 million (Q3 2025), $9.4 million (Q2 2025), and $14.8 million (Q1 2025).